Geode Capital Management LLC Decreases Position in Seer, Inc. (NASDAQ:SEER)

Geode Capital Management LLC cut its position in Seer, Inc. (NASDAQ:SEER) by 3.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 431,906 shares of the company’s stock after selling 14,423 shares during the period. Geode Capital Management LLC owned 0.73% of Seer worth $998,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd acquired a new position in Seer during the fourth quarter worth about $36,000. Corient Private Wealth LLC boosted its position in shares of Seer by 66.0% during the fourth quarter. Corient Private Wealth LLC now owns 33,200 shares of the company’s stock worth $77,000 after buying an additional 13,200 shares during the period. Barclays PLC grew its position in Seer by 34.1% in the 3rd quarter. Barclays PLC now owns 64,426 shares of the company’s stock valued at $127,000 after acquiring an additional 16,382 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Seer by 67.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 175,354 shares of the company’s stock worth $345,000 after buying an additional 70,671 shares in the last quarter. Finally, Peapod Lane Capital LLC purchased a new position in Seer in the fourth quarter valued at $991,000. 75.20% of the stock is owned by institutional investors and hedge funds.

Seer Stock Performance

Shares of Seer stock opened at $2.04 on Friday. The business has a 50-day simple moving average of $1.94 and a 200-day simple moving average of $2.16. Seer, Inc. has a one year low of $1.56 and a one year high of $2.63. The company has a market cap of $121.96 million, a PE ratio of -1.57 and a beta of 1.61.

Seer Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.